Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Barclays PLC

Barclays PLC raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 31.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 427,595 shares of the company's stock after purchasing an additional 102,848 shares during the quarter. Barclays PLC's holdings in Teva Pharmaceutical Industries were worth $7,705,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of TEVA. UMB Bank n.a. raised its stake in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock valued at $44,000 after purchasing an additional 2,067 shares in the last quarter. Smithfield Trust Co increased its holdings in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after buying an additional 980 shares during the last quarter. Claro Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the third quarter valued at approximately $52,000. Mark Sheptoff Financial Planning LLC bought a new position in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $57,000. Finally, Venturi Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $60,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. UBS Group upped their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, October 21st. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday. Finally, Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an "overweight" rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $20.88.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA traded up $0.11 during mid-day trading on Thursday, hitting $21.31. The stock had a trading volume of 14,443,077 shares, compared to its average volume of 9,431,179. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The company has a 50 day simple moving average of $17.69 and a 200-day simple moving average of $17.48. The stock has a market capitalization of $24.14 billion, a price-to-earnings ratio of -25.07, a P/E/G ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries Limited has a 52 week low of $10.34 and a 52 week high of $21.98.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of the firm's stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares of the company's stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.55% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.